Toll Free: 1-888-928-9744

Stroke - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 593 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Stroke - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Stroke - Pipeline Review, H1 2016', provides an overview of the Stroke pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Stroke
- The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects
- The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Stroke

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 8 Stroke Overview 9 Therapeutics Development 10 Stroke - Therapeutics under Development by Companies 12 Stroke - Therapeutics under Investigation by Universities/Institutes 20 Stroke - Pipeline Products Glance 22 Stroke - Products under Development by Companies 26 Stroke - Products under Investigation by Universities/Institutes 35 Stroke - Companies Involved in Therapeutics Development 37 Stroke - Therapeutics Assessment 125 Drug Profiles 142 Stroke - Recent Pipeline Updates 403 Stroke - Dormant Projects 543 Stroke - Discontinued Products 558 Stroke - Product Development Milestones 562 Appendix 573
List of Tables
Number of Products under Development for Stroke, H1 2016 29 Number of Products under Development for Stroke - Comparative Analysis, H1 2016 30 Number of Products under Development by Companies, H1 2016 31 Number of Products under Development by Companies, H1 2016 (Contd..1) 32 Number of Products under Development by Companies, H1 2016 (Contd..2) 33 Number of Products under Development by Companies, H1 2016 (Contd..3) 34 Number of Products under Development by Companies, H1 2016 (Contd..4) 35 Number of Products under Development by Companies, H1 2016 (Contd..5) 36 Number of Products under Development by Companies, H1 2016 (Contd..6) 37 Number of Products under Development by Companies, H1 2016 (Contd..7) 38 Number of Products under Investigation by Universities/Institutes, H1 2016 39 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 40 Comparative Analysis by Late Stage Development, H1 2016 41 Comparative Analysis by Clinical Stage Development, H1 2016 42 Comparative Analysis by Early Stage Development, H1 2016 43 Comparative Analysis by Unknown Stage Development, H1 2016 44 Products under Development by Companies, H1 2016 45 Products under Development by Companies, H1 2016 (Contd..1) 46 Products under Development by Companies, H1 2016 (Contd..2) 47 Products under Development by Companies, H1 2016 (Contd..3) 48 Products under Development by Companies, H1 2016 (Contd..4) 49 Products under Development by Companies, H1 2016 (Contd..5) 50 Products under Development by Companies, H1 2016 (Contd..6) 51 Products under Development by Companies, H1 2016 (Contd..7) 52 Products under Development by Companies, H1 2016 (Contd..8) 53 Products under Investigation by Universities/Institutes, H1 2016 54 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 55 Stroke - Pipeline by AB Science SA, H1 2016 56 Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2016 57 Stroke - Pipeline by Acticor Biotech, H1 2016 58 Stroke - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016 59 Stroke - Pipeline by Addex Therapeutics Ltd, H1 2016 60 Stroke - Pipeline by advanceCor GmbH, H1 2016 61 Stroke - Pipeline by Affibody AB, H1 2016 62 Stroke - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 63 Stroke - Pipeline by Anavex Life Sciences Corp., H1 2016 64 Stroke - Pipeline by Angion Biomedica Corp., H1 2016 65 Stroke - Pipeline by Antoxis Limited, H1 2016 66 Stroke - Pipeline by Aralez Pharmaceuticals Inc., H1 2016 67 Stroke - Pipeline by ArmaGen Inc., H1 2016 68 Stroke - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 69 Stroke - Pipeline by AstraZeneca Plc, H1 2016 70 Stroke - Pipeline by Athersys, Inc., H1 2016 71 Stroke - Pipeline by Bayer AG, H1 2016 72 Stroke - Pipeline by Bioasis Technologies Inc., H1 2016 73 Stroke - Pipeline by Biogen, Inc., H1 2016 74 Stroke - Pipeline by BioTime, Inc., H1 2016 75 Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 76 Stroke - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 77 Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016 78 Stroke - Pipeline by D-Pharm Ltd., H1 2016 79 Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 80 Stroke - Pipeline by DiaMedica Inc., H1 2016 81 Stroke - Pipeline by Digna Biotech, S.L., H1 2016 82 Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 83 Stroke - Pipeline by Fina Biotech, H1 2016 84 Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 85 Stroke - Pipeline by Glialogix, Inc., H1 2016 86 Stroke - Pipeline by Glucox Biotech AB, H1 2016 87 Stroke - Pipeline by Green Cross Corporation, H1 2016 88 Stroke - Pipeline by Grifols, S.A., H1 2016 89 Stroke - Pipeline by Huons Co., Ltd., H1 2016 90 Stroke - Pipeline by International Stem Cell Corporation, H1 2016 91 Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 92 Stroke - Pipeline by JN-International Medical Corporation, H1 2016 93 Stroke - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 94 Stroke - Pipeline by LegoChem Biosciences, Inc, H1 2016 95 Stroke - Pipeline by Living Cell Technologies Limited, H1 2016 96 Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016 97 Stroke - Pipeline by M et P Pharma AG, H1 2016 98 Stroke - Pipeline by Mapreg S.A.S., H1 2016 99 Stroke - Pipeline by Mast Therapeutics, Inc., H1 2016 100 Stroke - Pipeline by Medestea Research & Production S.p.A., H1 2016 101 Stroke - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016 102 Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 103 Stroke - Pipeline by Neuralstem, Inc., H1 2016 104 Stroke - Pipeline by Neuren Pharmaceuticals Limited, H1 2016 105 Stroke - Pipeline by Neuronax SAS, H1 2016 106 Stroke - Pipeline by Neurotec Pharma SL, H1 2016 107 Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 108 Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H1 2016 109 Stroke - Pipeline by New World Laboratories, Inc., H1 2016 110 Stroke - Pipeline by NoNO, Inc., H1 2016 111 Stroke - Pipeline by Omeros Corporation, H1 2016 112 Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 113 Stroke - Pipeline by Pfizer Inc., H1 2016 114 Stroke - Pipeline by PharmatrophiX, Inc., H1 2016 115 Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016 116 Stroke - Pipeline by Phoenix Biotechnology, Inc., H1 2016 117 Stroke - Pipeline by Phylogica Limited, H1 2016 118 Stroke - Pipeline by PhytoHealth Corporation, H1 2016 119 Stroke - Pipeline by Pluristem Therapeutics Inc., H1 2016 120 Stroke - Pipeline by Primary Peptides, Inc., H1 2016 121 Stroke - Pipeline by Q Therapeutics, Inc., H1 2016 122 Stroke - Pipeline by QR Pharma, Inc., H1 2016 123 Stroke - Pipeline by ReCyte Therapeutics, Inc., H1 2016 124 Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 125 Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 126 Stroke - Pipeline by ReNeuron Group Plc, H1 2016 127 Stroke - Pipeline by SanBio, Inc., H1 2016 128 Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016 129 Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016 130 Stroke - Pipeline by StemCells, Inc., H1 2016 131 Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 132 Stroke - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 133 Stroke - Pipeline by SynZyme Technologies, LLC, H1 2016 134 Stroke - Pipeline by Targazyme, Inc., H1 2016 135 Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 136 Stroke - Pipeline by TikoMed AB, H1 2016 137 Stroke - Pipeline by vasopharm GmbH, H1 2016 138 Stroke - Pipeline by Vicore Pharma AB, H1 2016 139 Stroke - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 140 Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016 141 Stroke - Pipeline by Xigen SA, H1 2016 142 Stroke - Pipeline by Zocere, Inc., H1 2016 143 Assessment by Monotherapy Products, H1 2016 144 Number of Products by Stage and Target, H1 2016 146 Number of Products by Stage and Mechanism of Action, H1 2016 153 Number of Products by Stage and Route of Administration, H1 2016 158 Number of Products by Stage and Molecule Type, H1 2016 160 Stroke Therapeutics - Recent Pipeline Updates, H1 2016 422 Stroke - Dormant Projects, H1 2016 562 Stroke - Dormant Projects (Contd..1), H1 2016 563 Stroke - Dormant Projects (Contd..2), H1 2016 564 Stroke - Dormant Projects (Contd..3), H1 2016 565 Stroke - Dormant Projects (Contd..4), H1 2016 566 Stroke - Dormant Projects (Contd..5), H1 2016 567 Stroke - Dormant Projects (Contd..6), H1 2016 568 Stroke - Dormant Projects (Contd..7), H1 2016 569 Stroke - Dormant Projects (Contd..8), H1 2016 570 Stroke - Dormant Projects (Contd..9), H1 2016 571 Stroke - Dormant Projects (Contd..10), H1 2016 572 Stroke - Dormant Projects (Contd..11), H1 2016 573 Stroke - Dormant Projects (Contd..12), H1 2016 574 Stroke - Dormant Projects (Contd..13), H1 2016 575 Stroke - Dormant Projects (Contd..14), H1 2016 576 Stroke - Discontinued Products, H1 2016 577 Stroke - Discontinued Products (Contd..1), H1 2016 578 Stroke - Discontinued Products (Contd..2), H1 2016 579 Stroke - Discontinued Products (Contd..3), H1 2016 580


List of Figures
Number of Products under Development for Stroke, H1 2016 29 Number of Products under Development for Stroke - Comparative Analysis, H1 2016 30 Number of Products under Development by Companies, H1 2016 31 Number of Products under Investigation by Universities/Institutes, H1 2016 39 Comparative Analysis by Late Stage Development, H1 2016 41 Comparative Analysis by Clinical Stage Development, H1 2016 42 Comparative Analysis by Early Stage Products, H1 2016 43 Assessment by Monotherapy Products, H1 2016 144 Number of Products by Top 10 Targets, H1 2016 145 Number of Products by Stage and Top 10 Targets, H1 2016 145 Number of Products by Top 10 Mechanism of Actions, H1 2016 152 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 152 Number of Products by Top 10 Routes of Administration, H1 2016 157 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 157 Number of Products by Top 10 Molecule Types, H1 2016 159 Number of Products by Stage and Top 10 Molecule Types, H1 2016 159

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify